• Skip to primary navigation
  • Skip to content
  • Skip to footer
  • Estudantes
    • Webmail
    • Moodle
    • Ensino à Distância
    • NetP@
    • Biblioteca
    • Escola Doutoral
    • Serviços Académicos
    • Trabalhar no IHMT
  • Staff
    • Webmail
    • Área de Docentes
    • Área de Não-Docentes

IHMT

Instituto de Higiene e Medicina Tropical

PortuguêsEnglishFrançaisDeutschEspañol

Universidade Nova de Lisboa

  • Ensino
    • Doutoramentos
    • Mestrados
    • Ensino à Distância
    • Cursos de Especialização
    • Cursos de Curta Duração
    • Apoio ao Desenvolvimento
  • Investigação
    • GHTM
  • Doenças Tropicais
    • Glossário
    • Consulta do Viajante
    • Museu
      • Peça do Mês
    • Vídeos
    • MosquitoWeb
  • Unidades de Ensino e de Investigação
  • 5º Congresso Nacional de Medicina Tropical
Home / Publicações / A near-full length genotypic assay for HCV1b

A near-full length genotypic assay for HCV1b

  • Autores: Camacho RJ, Cuypers L, Kerremans L, Nevens F, Snoeck J, Van Dooren S, Vandamme AM, Verbeeck J, Vrancken B, Vuagniaux G
  • Ano de Publicação: 2014
  • Journal: Journal of Virological Methods
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/25245140

A near-full genome genotypic assay for HCV1b was developed, which may prove useful to investigate antiviral drug resistance, given new combination therapies for HCV1 infection. The assay consists of three partially overlapping PCRs followed by Sanger population or Illumina next-generation sequencing. Seventy-seven therapy-naïve samples, spanning the entire diversity range of currently known HCV1b, were used for optimization of PCRs, of which ten were sequenced using Sanger and of these ten, four using Illumina. The median detection limits for the three regions, 5’UTR-NS2, E2-NS5A and NS4B-NS5B, were 570, 5670 and 56,670 IU/ml respectively. The number of Illumina reads mapped varied according to the software used, Segminator II being the best performing (81%). Consensus Illumina and Sanger sequencing results accord largely (0.013% major discordances). Differences were due almost exclusively to a larger number of ambiguities (presumably minority variants) scored by Illumina (1.50% minor discordances). The assay is easy to perform in an equipped laboratory; nevertheless, it was difficult to reach high sensitivity and reproducibility, due to the high genetic viral variability. This assay proved to be suitable for detecting drug resistance mutations and can also be used for epidemiological research, even though only a limited set of samples was used for validation.

A near-full length genotypic assay for HCV1b

  • Autores: Camacho RJ, Cuypers L, Kerremans L, Nevens F, Snoeck J, Van Dooren S, Vandamme AM, Verbeeck J, Vrancken B, Vuagniaux G
  • Ano de Publicação: 2014
  • Journal: Journal of Virological Methods
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/25245140

A near-full genome genotypic assay for HCV1b was developed, which may prove useful to investigate antiviral drug resistance, given new combination therapies for HCV1 infection. The assay consists of three partially overlapping PCRs followed by Sanger population or Illumina next-generation sequencing. Seventy-seven therapy-naïve samples, spanning the entire diversity range of currently known HCV1b, were used for optimization of PCRs, of which ten were sequenced using Sanger and of these ten, four using Illumina. The median detection limits for the three regions, 5’UTR-NS2, E2-NS5A and NS4B-NS5B, were 570, 5670 and 56,670 IU/ml respectively. The number of Illumina reads mapped varied according to the software used, Segminator II being the best performing (81%). Consensus Illumina and Sanger sequencing results accord largely (0.013% major discordances). Differences were due almost exclusively to a larger number of ambiguities (presumably minority variants) scored by Illumina (1.50% minor discordances). The assay is easy to perform in an equipped laboratory; nevertheless, it was difficult to reach high sensitivity and reproducibility, due to the high genetic viral variability. This assay proved to be suitable for detecting drug resistance mutations and can also be used for epidemiological research, even though only a limited set of samples was used for validation.

Footer

  • Sobre o IHMT
  • Organização
  • Docentes e Investigadores
  • Serviços Académicos
  • Recursos Humanos
  • Trabalhar no IHMT
  • Instrumentos de Gestão
  • Associação de Alunos e Amigos
  • Parcerias
  • Biblioteca
  • Biobanco GHTM-IHMT – Biotropical Resources
  • Ensino
  • Investigação
  • Cooperação e Desenvolvimento
  • Qualidade

Contactos

Rua da Junqueira, 100
1349-008 Lisboa
Portugal
+351 213 652 600
+351 213 632 105

Contactos dos Serviços

Marcação de consultas:
+351 213 652 630/90
+351 213 627 553
medicina.viagens@ihmt.unl.pt

Subscrever newsletter

Follow us

  • Facebook
  • LinkedIn
  • YouTube
© Copyright 2021 IHMT-UNL Todos os Direitos Reservados.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    Project UID/Multi/04413/2013

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok